Anthrogenesis Corporation

Celularity Inc.

Neurodynamics, Inc.

Other

Myos Rens Technology Inc.

Anthrogenesis Corproation

Celgene Corporation

Signal Pharmaceuticals, Inc.

Clarity Acquisition II LLC

Qian Ye

Jia-lun Wang

James W. Edinger

Robert J. Hariri

Robert J Hariri

James W Edinger

Xiaokui Zhang

Jia-Lun Wang

Jamshid B Ghajar

Vanessa R Voskinarian-Berse

Lin Kang

Fathali G Ghadjar

Kristen S Labazzo

Eric Law

Sascha Dawn Abramson

Ryhor Harbacheuski

RoseAnn Murray

Jai-Lun Wang

Casper Paludan

Andrew L Zeitlin

Mohammad A Heidaran

Herbert Faleck

Ajai Pal

Marian Pereira

Wolfgang Hofgartner

Stewart Abbot

Neerav Dilip Padliya

Jodi P Gurney

Kyle W H Chan

David I Stirling

Uri Herzberg

Vladimir Jankovic

Jennifer Paredes

Brian P Murphy

Steven Alan Fischkoff

Neerav D Padliya

Kyle Chan

Mohit B Bhatia

Roseann Murray

Bhavani Stout

Laure A Moutouh-De Parseval

Fathali Ghahremani-Ghadjar

Stephen Jasko

Mohit Bhatia

Aleksandar Francki

Aleksandr Kaplunovsky

Shmuel Yaccoby

Kathy Karasiewicz-Mendez

Andy Zeitlin

Carlon Colker

Han Myint

Mohamad Hussein

Andrew Morschauser

Aleksander Francki

Janice M Smiell

Allan Reduta

Katarzyna Karasiewicz-Mendez

Andrea Nordberg

Ivana Djuretic

Stacy Herb

Keith Wilson

Qian Yi

Jia-Iun Wang

Aleksandr M Kaplunovsky

Patricia A Murphy

Steven Jasko

Marian Periera

Vanessa A Voskinarian-Berse

Laure Moutouh-De Parseval

Kristine Erikson Johnson

Vanessa Voskinarian-berse

Kyle W Chan

Vanessa Voskinarian-Berse

Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.

Treatment of inflammatory diseases using placental stem cells

Provided herein are placental stem cells that exhibit increased survival ('enhanced placental stem cells'), compositions comprising such placental stem cells, and methods of using such placental stem cells and compositions.

Enhanced placental stem cells and uses thereof

Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three-stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells. In certain embodiments, the NK cells produced by the three-stage methods described herein are used in combination with IL-2.

Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells

Provided herein are compositions of placenta-derived adherent cell exosomes and methods of making and using the same. In one aspect, provided herein are compositions comprising exosomes produced by and/or derived from placental cells, e.g., placenta-derived adherent cells. In certain embodiments, the exosomes provided herein are produced by placenta-derived adherent cells that have been cultured in vitro for, e.g., 1, 2, 3, 4, 5, 6 or more passages.

Placenta-derived adherent cell exosomes and uses thereof

Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC&#x2122;).

Treatment of pain using placental stem cells

Embodiments of the present invention are generally related to methods of obtaining effective amount of avian follistatin. More specifically, embodiments of the present invention relate to products comprising avian follistatin, and methods of optimizing the same based on avian follistatin concentrations utilized during the manufacturing process. In one embodiment of the present invention, a method of creating a consumable product for treatment of a muscle degenerating disease having avian follistatin comprises selecting an avian egg based upon a desired threshold of avian follistatin concentration therein; extracting material from the avian egg, the material comprising avian follistatin; and processing the material with one or more excipients to yield the consumable product.

Method of obtaining effective amounts of avian follistatin

Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34CD45stem cells from placenta.

CD34,CD45placental stem cell-enriched cell populations

The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.

Placental stem cell populations

Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.

Therapy with cells from human placenta and hematopoietic cells

A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.

Method of collecting placental stem cells

Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.

Methods and compositions for treatment of bone defects with placental cell populations

Provided herein are methods of treatment of an individual having amyotrophic lateral sclerosis, comprising administering to the individual a therapeutically effective amount of placental stem cells, e.g., tissue culture surface-adherent placental stem cells (PDACs). In one aspect, provided herein is a method of treating amyotrophic lateral sclerosis (ALS) comprising administering to an individual having ALS a therapeutically effective amount of placental stem cells. In certain embodiments, 'therapeutically effective' means an amount effective to reduce or ameliorate one or more symptoms of ALS.

Treatment of amyotrophic lateral sclerosis using placental stem cells

Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.

Natural killer cells from placenta

Provided herein are methods of evaluating potential antitumor compounds, and thereby identifying antitumor compounds, using placenta or a portion thereof and tumor cells, and compositions for accomplishing the same. In one embodiment, provided herein is a method of determining whether a potential antitumor compound is effective against a plurality of tumor cells, comprising introducing a plurality of tumor cells to, e.g., into or onto, a mammalian placenta or portion thereof; contacting said plurality of tumor cells for a period of time with said antitumor compound; and determining whether said antitumor compound is effective against said tumor cells, wherein said antitumor compound is effective against said tumor cells if said antitumor compound over said period of time reduces the number of said tumor cells or reduces the growth rate of said tumor cells.

Identification of antitumor compounds using placenta

The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.

Immunomodulation using placental stem cells

Growing community of inventors

Bernardsville, NJ, United States of America

Robert J Hariri